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ABSTRACT
Unrelated umbilical cord blood (UCB) transplantation has recently been explored in an increasing number of
adult patients. The relative ease of procurement and the lower-than-anticipated risk of severe acute graft-
versus-host disease has made UCB transplantation an appealing alternative to bone marrow–derived hema-
topoietic stem cells. The use of reduced-intensity or nonmyeloablative preparative regimens to allow engraft-
ment of UCB broadens the scope of patients who may benefit from allogeneic immunotherapy, including
elderly and medically infirm patients with no matched sibling donor. This review summarizes the available data
on the use of UCB as an alternative source of hematopoietic stem cell transplantation in adult patients.
© 2004 American Society for Blood and Marrow Transplantation
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The success of the ﬁrst allogeneic umbilical cord
lood (UCB) transplantation in October 1988 in a
hild with Fanconi anemia [1] opened the way to an
ntire new ﬁeld in the domain of allogeneic hemato-
oietic stem cell transplantation (HSCT). After this
uccessful transplantation procedure, it is estimated
hat more than 2000 UCB transplantations (UCBT)
ave been performed worldwide from both related
nd unrelated donors (UD) [2], although many of
hese transplantations have not been reported in ref-
reed publications for evaluation. UCB has now been
ccepted as an alternative source for HSCT in chil-
ren. The rapid expansion in the use of UCB for
ransplantation is the culmination of several factors,
ost of which are to address the limitations encoun-
ered in the use of HLA-matched related hematopoi-
tic stem cells: these include (1) a lack of suitable
LA-matched donors; (2) complications of graft-ver-
us-host disease (GVHD) associated with HLA dis-
arities, particularly if bone marrow from an HLA- a
B&MTatched UD is used [3,4]; and (3) the cumbersome
rocess of identifying, typing, and harvesting from an
D, with a median time interval between initiation of
search and donation of marrow of approximately 4
onths [5].
Unrelated UCB offers many practical advantages
s an alternative source of stem cells, including (1) the
elative ease of procurement and the fact that stem
ells are available considerably faster than are unre-
ated bone marrow grafts [6]; (2) the absence of risk
or mothers and donors; (3) the reduced likelihood of
ransmitting infections, particularly cytomegalovirus
CMV); (4) the ability to store fully tested and HLA-
yped cord blood (CB), in the frozen state, available
or immediate use [7]; (5) potential reduced risk of
VHD [8]; (6) less stringent criteria for HLA match-
ng for donor/recipient selection; and (7) absence of
onor attrition.
The past 12 years have witnessed an explosion of
dvances leading to an increased understanding of the
iological characteristics of UCB, in parallel with its
pplications in clinical transplantations. UCB banks
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2ave been established for related and unrelated
CBT, and more than 30000 units are currently avail-
ble [9]. Although CB transplantation from both related
onors and UDs has demonstrated encouraging results
n pediatric patients with hematologic malignancies or
arrow failure syndromes, there is still limited applica-
ility in adults. The lower number of hematopoietic
tem cells in CB compared with bone marrow, together
ith preliminary data showing the importance of cell
ose for the outcome of UCBT, has been a cause for
aution with its use in adult patients [10,11]. Also, most
CBT involved the use of myeloablative preparative
egimens that are known to be associated with consid-
rable morbidity and mortality. Despite having suitable
CB donors, many older patients and patients with
omorbidities will be prevented from receiving UCBT
ecause of the unacceptable toxicities from the standard
onditioning regimens.
Recently, older recipients of allogeneic HSCT
ave been treated successfully after a variety of less
ntense nonmyeloablative (NM) conditioning regi-
ens [12-14]. These encouraging observations were a
esult of selective ablation of the lymphoid cells by
sing lymphotoxic agents, large progenitor cell doses,
nd drugs to prevent host-versus-graft disease, as well
s GVHD. On the basis of these encouraging obser-
ations, it has been hypothesized that a reduced-in-
ensity preparative regimen would allow engraftment
f the UCB stem cells. Although the total numbers of
ononuclear cells are limited, the progenitor content
nd the proliferative potential of CB cells are high.
herefore, these CB cells could establish full donor
himerism with a lower risk of transplantation-related
orbidity in older patients and in patients who are
eemed unﬁt to undergo transplantation with conven-
ional myeloablative preparative regimens. UCB, with
ts unique cellular characteristics as listed previously,
an potentially overcome the problem of limited avail-
bility of suitable related and unrelated stem cell do-
ors and thereby broaden the scope of patients who
ay beneﬁt from NM HSCT.
This review summarizes the available data on the
se of UCB as an alternative source of hematopoietic
tem cells for allogeneic transplantation in adult pa-
ients, with an overview of the current knowledge on
ome areas of interest, including a comparative anal-
sis in clinical outcome between adult and pediatric
atients, the difference between myeloablative and
M approaches, and several areas of uncertainty on
he NM approach.
CBT USING MYELOABLATIVE PREPARATIVE
EGIMENS
UCBT in adults and children from related donors
nd UDs after myeloablative preparative regimens has
een shown to produce successful engraftment in both phildren and adults with hematologic malignancies,
arrow failure syndrome, and immune deﬁciencies.
he results of several large series have been reported
n the peer-reviewed literature over the past 7 years
8-11,15-22]. The myeloablative preparative regimens
sed in these studies were either total body irradiation
TBI) based or chemotherapy based, with inclusion of
ntithymocyte globulin in some of the patients. The
ata from these UCBT registries, in which most re-
ipients are children, point to a signiﬁcant delay in the
ime of neutrophil recovery, with the median time to
n absolute neutrophil count (ANC) 500/L rang-
ng between 22 and 30 days. The overall probability of
ngraftment was in the range of 80% to 90%. Despite
higher degree of HLA disparity, grade II to IV
VHD in those unrelated UCB recipients was lower
han in recipients of unrelated bone marrow or pe-
ipheral blood grafts from adult donors. It is impor-
ant to note that the number of nucleated cells in the
nfused UCB inﬂuences the speed of recovery of neu-
rophils and platelets. In a recently published study,
agner et al. [20] demonstrated the importance of
D34 cell dose in determining the outcome after
nrelated UCBT. Patients receiving a CD34 cell dose
1.7  105/kg body weight have a slower neutrophil
ecovery at a median of 34 days (range, 17-54 days), an
nferior likelihood of engraftment, and a higher inci-
ence of treatment-related mortality.
LINICAL RESULTS IN ADULT PATIENTS
In comparison to the published studies on pediat-
ic patients, the clinical data on the use of UCBT in
dult patients is relatively limited: 3 in peer-reviewed
ublished articles [9,21,22] and the remaining either
n abstract form [23-27] or integrated into the studies
hat have been conducted in predominantly pediatric
opulations [10,11,20,28]. The clinical results of the
tudies that were conducted exclusively in adult pa-
ients are summarized in the following paragraphs and
n Table 1.
Laughlin et al. [21] published one of the ﬁrst
ulticenter studies of 68 adults with life-threatening
ematologic disorders (79% hematological malignan-
ies; 21% bone marrow failure syndrome or inborn
rror of metabolism) who were receiving HLA-mis-
atched unrelated UCBT. Approximately one third
f the patients had advanced or refractory hemato-
ogic malignancies before transplantation. The me-
ian age of the patients was 31.4 years (range, 17.6-
8.1 years), and the median weight was 69.2 kg (range,
0.9-115.5 kg). More than two third of the patients
eceived grafts that were mismatched for 2 HLA
ntigens. The probability of neutrophil recovery dur-
ng the ﬁrst 42 days after transplantation was 90%.
he median time required for an ANC 500/L and
latelets 20000/L was 27 days (range, 13-59 days)
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Cord Blood Transplants in Adults
Bnd 58 days (range, 35-142 days), respectively. As in
hildren, rapid recovery occurred in patients who re-
eived the highest number of nucleated cells in UCB
efore freezing and CD34 cells after thawing. De-
pite HLA mismatches in more than two thirds of the
atients, the incidence of GVHD was low. Only 11
20%) of the 55 evaluable patients developed grade III
r IV GVHD within the ﬁrst 100 days after transplan-
ation. With a median follow-up of 22 months (range,
1-51 months), 19 (28%) of the 68 patients were alive,
nd 18 were disease free. The event-free survival
EFS) at 40 months was 26%. Notably, the presence
f a higher CD34 cell dose—1.2  105/kg—was
ssociated with improved EFS.
Sanz et al. [22] reported the results of unrelated
CBT after a standardized preparative and GVHD
egimen in a series of 22 adult patients with hemato-
ogic malignancies. The median age was 29 years
range, 18-46 years), and the median weight was 69.5
g (range, 41-85 kg). HLA matching was 6 of 6 in 1
ase, 5 of 6 in 13 cases, and 4 of 6 in 8 cases. The
edian number of nucleated cells infused was 1.71 
07/kg (range, 1.01-4.96  107/kg). All 20 patients
ho survived for 30 days experienced myeloid en-
raftment. The median time to reach an ANC0.5
09/L and platelets 20  109/L was 22 days and 69
ays, respectively. All patients except 1 developed
cute GVHD. Seven patients developed acute GVHD
bove grade II, and 9 of 10 patients at risk developed
hronic GVHD. Disease-free survival (DFS) at 1 year
as 53%. Patients younger than 30 years had a better
FS than the older age group. Of note, a greater
roportion of patients in this series presented with
ore favorable disease status at transplantation as
ompared with most other adult series; 13 (59%) pa-
ients had either chronic myeloid leukemia (CML) in
rst chronic phase or acute leukemia in ﬁrst remission.
Gluckman [9] analyzed the outcomes of 108 adults
ho received unrelated UCBT and who were re-
orted to the Eurocord registry [23]. The median age
as 26 years (range, 15-53 years) for the entire group
f patients, of which most had leukemia or lymphoma.
he median weight was 60 kg (range, 35-110 kg).
ith a median infused nucleated cell dose of 1.7 
07/kg, the probability of 81% myeloid engraftment
t day 60 was attained. The median time for ANC to
xceed 500/L and platelets to exceed 20000/L was
2 days (range, 13-57 days) and 129 days (range,
6-176 days), respectively. The overall 1-year survival
as 27%, and more favorable outcomes were seen
mong patients with chronic disease or leukemia in
emission. The estimated transplant-related mortality
t day 100 was 54%. Disease in the chronic phase or
emission, an infused nucleated cell dose 2.0  107/
g, and transplantation performed after January 1998
ere identiﬁed as factors that were associated with t
B&MTower treatment-related mortality (TRM) within the
rst 100 days.
Goldberg et al. [24] performed 19 unrelated
CBT in adult patients with hematologic malignan-
ies or myelodysplastic syndrome, and several patients
ad high-risk diseases or had experienced treatment
ailure with prior autologous transplantation. The me-
ian age was 48 years (range, 20-59 years), and the
edian weight was 69 kg (range, 52-126 kg). The
egree of HLA matching of the UCB units was 6 of 6
n 4, 5 of 6 in 8, and 4 of 6 in 7 patients. The median
nfused cell total nucleated dose was 1.8  107/kg.
en patients in this study group received ex vivo
xpanded UCB units. The median time to ANC
500/L was 28 days, and the median time to plate-
ets 20000/L was 56 days. The 100-day overall
urvival was 32%. One-year overall survival was 20%
n good-risk and 21% in poor-risk patients.
The Cord Blood Transplantation Study Group
ecently updated the results of their National Heart,
ung, and Blood Institute–sponsored, prospectively
onducted pilot study on the use of unrelated UCBT
n patients requiring allogeneic transplantation [26].
he 34 adult patients in the study, most of whom had
oor-risk hematologic malignancies, were at a median
ge of 34.5 years (range, 18.2-55 years). Most subjects
n  23) were matched at 4 of 6 HLA alleles; 10
ubjects were matched at 5 of 6 alleles and 1 at 6 of 6
lleles. The conditioning regimen was TBI/cyclo-
hosphamide for 27 patients and busulfan/melphalan
or 7 patients. The median nucleated cell dose infused
as 1.73  107/kg (range, 11.1-37.5  107/kg). Pri-
ary graft failure was seen in 8 (28%) of the evaluable
atients. Engraftment occurred in 22 of the 29 evalu-
ble subjects, with a cumulative incidence of 72%
chieved by day 60. Grade II to IV acute GVHD and
rade III to IV GVHD was seen in 11 (38%) and 6
21%) of the 29 evaluable patients, respectively. Four
atients were alive between 373 and 743 days after
ransplantation. Kaplan-Meier survival estimates, ex-
luding the 4 early deaths, were 47% and 30% at 100
nd 180 days, respectively. Notably, overall survival
as not inﬂuenced by age stratiﬁcation, degree of
atching, or cell dose. The poor survival outcome in
his cohort of patients reﬂects the poor-risk subjects
nrolled onto the study.
Iseki et al. [29] reported one of the largest series of
dult unrelated UCB recipients outside North Amer-
ca and European transplant centers. In their series of
0 Japanese patients with hematologic malignancies or
yelodysplastic syndrome, the median age, weight,
nd infused nucleated doses were 38 years, 52 kg, and
.39  107/kg, respectively. The median time for
eutrophil recovery (ANC 500/L) and platelet re-
overy (50000/L) was 22 days and 38 days, respec-
ively. Early death occurred in 3 patients. Eight pa-
ients developed acute GVHD grade II, and 1 patient
3
Table 1. Studies of Unrelated Umbilical Cord Blood Transplantation in Adults
Variable Laughlin et al. Sanz et al. Eurocord Goldberg et al. Cornetta et al. Iseki et al. Ooi et al. Duke University
Reference No. 21 22 9,23 24 26 27 30
No. of patients 68 22 108 19 34 30 13 57*
Median age, y (range) 31.4 (17.6-58.1) 29 (18-46) 26 (15-53) 48 (20-59) 34.5 (18.2-55) 38 (NA) 40 (20-51) 31 (18-58)
Median weight, kg (range) 69.2 (40.9-115.5) 70 (41-85) 60 (35-110) 69 (52-126) NA 52 (NA) 51 (43-68) 70 (46-110)
Diseases (n)
Hematologic malignancies 54 21 96 18 32 26 11 50
Bone marrow failure
syndrome/MDS 13 1 12 1 2 4 2 6
Inborn error of
metabolism 1 0 0 0 0 0 0 1
Number of HLA loci
disparities (n)
0 2 1 6 4 1 NA 0 2
1 18 13 38 8 10 4 8
2 37 8 51 7 23 7 44
3 11 0 13 0 0 2 3
Preparative regimen
TBI-based/ATG
(n  51)
Thio/Bu/Cy/ATG
(n  21) NA
Cy/TBI/ATG
(n  13) Cy/TBI (n  27) NA
Cy/TBI/Ara-C/G-
CSF (n  13)
Mel/TBI/ATG
(n  29)
Bu-based/ATG
(n  14)
Thio/Flu/ATG
(n  1)
Mel/TBI/ATG
(n  4) Bu/Mel (n  7) Mel/Bu/ATG (n  2)
Others/ATG
(n  4) Bu/Cy (n  2) Cy/Bu/ATG (n  2)
TAI/Cy/ATG
(n  1)
Cy/TBI/ATG (n  8)
GVHD prophylaxis
CsA/Pred
(n  NA) CsA/Pred (n  22)
CsA/Pred
(n  77)
CsA/Pred
(n  13) NA
CsA
(n  4) CsA/MTX (n  13) CsA (n  1)
CsA (n  NA)
Others
(n  31)
FK506/Pred
(n  6)
CsA/MTX
(n  26) CsA/Pred (n  56)
Median time to
engraftment, d (range)
ANC >500/L 27 (13-59) 22 (13-52) 32 (13-60) 28 (NA) 28.5 (13-55) 22 (NA) 22.5 (19-35) 26 (12-55)
Platelets >20 000/L 58 (35-142) 69 (49-153) 129 (26-176) 56 (NA) NA 26 (NA)† 49 (30-164)‡ 84 (35-167)
Probability of myeloid
engraftment 90% by 42 d 100% at 60 d 81% by day 60 75% by day 60 72% at day 60 NA
12/13 (92%) patients
engrafted 80% at day 50
GVHD, n (probability; %)
Acute grade II-IV 33 (60%) 16 (NA) 44 (38) NA 11 (38%) 8 (NA) 9§ 17 (41%)
Acute grade III-IV 11 (20%) 7 (NA) 27 (NA) NA 6 (21%) 1 (NA) — 9 (22%)
Chronic/patients at risk 12/33 9/10 15/58 NA NA NA 8/11 8/25
Median cell dose (range)
NC infused (107/kg) 1.6 (0.6-4) 1.71 (1.01-4.96) 1.71 (0.2-6) 1.8 (0.4-5.3) 1.73 (1.11-3.75) 2.39 (NA) 2.43 (2.09-4.06) 1.5 (0.54-2.78)
CD34 cells infused
(105/kg) 1.2 (0.2-16.7) 0.79 (0.27-2.60) NA NA NA NA NA 1.37 (0.02-12.45)
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Table 1 continued. Studies of Unrelated Umbilical Cord Blood Transplantation in Adults
Variable Laughlin et al. Sanz et al. Eurocord Goldberg et al. Cornetta et al. Iseki et al. Ooi et al. Duke University
TRM (%) 50% at 100 d 43% at 100 d 54% at 100 d NA NA NA 0% 56%
Survival (%) NA NA 27% at 1 y 20% for good
risk and 21%
for poor risk
at 1 y
30% at 180 d 76% at 3 y 76.2% at 2 y 19% at 3 y
EFS (%) 26% at 40 mo 53% at 1 y 21% at 1 y NA NA NA NA 15% at 3 y
Findings and comments (1) EFS is better
in patients
receiving graft
with CD34
cell >1.2 
105/kg
(2) EFS
independent
of HLA
disparity, age,
and type of
malignant
disorder
(3) Engraftment
is influenced
by the
number of NC
in UCB before
freezing and
CD34 after
thawing
(1) The series used
a standardized
conditioning
regimen and
GVHD
prophylaxis
regimen
(2) Patients, under
the age of 30 y
had significantly
better survival
(1) 100-d TRM
was lower in
patients
with disease
in chronic
phase or
remission,
NC dose
infused >2.0
 107/kg
and
transplantation
performed
after
January
1998
(2) NC infused
>1.7  107/
kg improved
neutrophil
recovery
10 patients
received ex
vivo expanded
UCBT
(1) Survival was
not influenced
by age, degree
of matching, or
cell dose
(2) The high
mortality and
relapse reflect
the poor-risk
patients
enrolled
(1) All except 1
patient received
UCB transplant as
an up-front
treatment (not
after remission
consolidation)
(2) All patients
received >2  107
NC per kilogram
weight, perhaps
because of smaller
size of patients
(median weight, 51
kg)
(1) CD34 cell dose
infused correlated
with rate of
platelet recovery
(2) Age >31 y was a
significant
predictor of
poorer event-free
survival
NA indicates not available; TRM, treatment-related mortality; NC, nucleated cell dose; TAI, thoracoabdominal radiation; Ara-C, cytarabine arabinoside; Thio, thiotepa; ATG, antithymocyte globulin;
Bu, busulfan; Flu, ﬂudarabine; Cy, cyclophosphamide; Mel, melphalan; Pred, prednisolone; FK506, tacrolimus; MDS, myelodysplastic syndrome.
*Nineteen of the 57 patients were included in the study published by McLaughlin et al.
†Platelet 50 000/L.
‡All had MDS-related secondary acute myeloid leukemia.
§Nine of 12 evaluable patients had acute GVHD.
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6eveloped grade III GVHD. The overall survival was
6% at 3 years.
In another Japanese series reported by Ooi et al.
30], 13 patients with advanced myelodysplastic syn-
rome received 1 to 3 HLA antigen–mismatched
nrelated UCB infusion after a myeloablative pre-
arative regimen containing granulocyte colony-
timulating factor (G-CSF) and cytosine arabinoside in
ombination with the standard TBI and cyclophospha-
ide regimen. The median age of the patients was 40
ears (range, 21-50 years), the median weight was 51 kg
range, 43-68 kg), and the median cell dose was 2.43 
07/kg of nucleated cells. Of note, before transplanta-
ion, 8 of the 13 patients did not receive induction
herapy, and 4 of the 5 patients who received induction
herapy could not achieve complete remission. Myeloid
econstitution occurred in 12 patients (92%), and the
edian time for neutrophil recovery (ANC 500/L)
nd self-sustained platelet recovery (50000/L) was
2.5 days and 49 days, respectively. The probability of
FS at 2 years was 76.2%.
At Duke University, 57 patients with both malig-
ant and nonmalignant hematologic diseases under-
ent unrelated UCBT between January 1996 and
anuary 2002. Nineteen of these patients were in-
luded in the multicenter study published in 2001
21]. The follow-up on surviving patients has been
xtended from that study by 22 months, with an ad-
itional 38 patients included for analysis. The median
ge was 31 years (range, 18-58 years), and the median
eight was 70 kg (range, 46-110 kg). HLA matching
etween donor and recipient was 3 of 6 in 3 patients, 4
f 6 in 44 patients, 5 of 6 in 8 patients, and 6 of 6 in 2
atients. The median infused nucleated cell dose was
.50  107/kg (range, 0.54-2.78  107/kg), and the
edian infused CD34 cell dose was 1.37  105/kg
range, 0.02-12.45  105/kg). Forty-one of the 57 pa-
ients had evidence of neutrophil engraftment, reaching
n ANC of 500/L at a median of 26 days (range,
2-55 days) with an untransfused platelet count of
0000/L at a median of 84 days (range, 35-167 days).
he number of CD34 cells correlated with the rate of
latelet recovery. Acute GVHD of grade III or IV de-
eloped in 9 of 41 evaluable patients. Chronic GVHD
as seen in 8 patients who survived 100 days. With a
edian follow-up of 1670 days (range, 67-2251 days) for
he surviving patients (n  11), the overall survival and
FS at 3 years were 19% and 15%, respectively. Nota-
ly, patients who were 31 years or younger had a signif-
cantly better EFS than those who were older.
OMPARATIVE ANALYSIS OF UNRELATED UCBT IN
HILDREN AND ADULTS
ematopoietic Recovery and Engraftment
Comparative studies by Eurocord in pediatric pa-
ients have suggested that as compared with allogeneic narrow transplant recipients, UCBT recipients have a
ower engraftment rate and more delayed hematopoi-
tic recovery [8,31]. The median times for neutrophil
ecovery to ANC recovery and platelet recovery
20000/L) in unrelated UCB recipients were sig-
iﬁcantly delayed: 32 days (range, 11-56 days) and 81
ays (range, 16-159 days), respectively, for unrelated
CBT recipients as compared with 18 days (range,
0-40 days) and 29 days (range, 8-141 days) for unre-
ated marrow recipients [31]. The higher risk of graft
ailure and the delay in hematopoietic recovery may
e related to several factors, including the lower nu-
leated cell and CD34 cell doses with the UCB grafts
s compared with the marrow allografts [32-34]; fac-
ors such as immaturity of stem cells, which might
eed more cell divisions before differentiation to mar-
ow progenitors; and the lack of subpopulations to
acilitate engraftment [35]. However, a study per-
ormed by the University of Minnesota reported a
ifferent outcome in terms of engraftment. In their
atched-pair analysis comparing twenty-six 0 to 3
LA-mismatched unrelated UCB recipients with 26
atched unrelated unmanipulated marrow recipients,
eutrophil recovery was signiﬁcantly delayed in the
nrelated UCB recipients, but there was no signiﬁcant
ifference in terms of the overall engraftment rate at
ay 45 and platelet recovery.
The important correlation between nucleated cell
ose and rate of engraftment in unrelated UCBT
atients has been demonstrated by the data from New
ork Blood Bank and the Eurocord registry [10,11]. A
ecent study published by investigators from the Uni-
ersity of Minnesota has shown that recipients of
CB grafts containing CD34 cells 1.7  105/kg
ad a incidence of engraftment similar to that ob-
erved in unrelated marrow allograft recipients [20].
The concern of limited cell doses leading to a
igher risk of primary graft failure in adults is related
o the disproportionate difference between the num-
er of nucleated cells in the UCB graft and the adult
ody weight, giving rise to relatively fewer infused
ells per kilogram of the recipient body weight, espe-
ially in heavier patients. However, the available data
n adult recipients of unrelated UCBT thus far have
hown that UCB contained sufﬁcient numbers of he-
atopoietic stem cells to achieve engraftment. The
bserved primary graft failure rate was approximately
0% to 20%, the median day to neutrophil engraft-
ent (ANC 500/L) ranged between 22 and 32
ays, and the probability of engraftment by day 60
anged between 70% and 100%. These results seem
omparable to those observed in the pediatric series,
n which the median time for neutrophil engraftment
anged between 25 and 32 days and the probability of
yeloid engraftment ranged between 80% and 90%
10,11,28,31,36]. Similar to pediatric patients, the
eutrophil and platelet recovery in adult UCB recip-
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Bents were signiﬁcantly delayed compared with the
arrow allograft recipients.
In 2 of the largest adult series, the nucleated cell
ose was associated with the rate of neutrophil and
latelet recovery [9,21]. In the multicenter study by
aughlin et al. [21], neutrophil engraftment was faster
n adult patients who underwent transplantation with
cryopreserved nucleated cell dose 1.87  107/kg.
n the Eurocord analysis, an infused nucleated cell
ose of1.7 107/kg was associated with more rapid
eutrophil recovery [23].
Ooi et al. [37], in a non–matched-pair analysis,
erformed a clinical comparison of 8 unrelated UCBT
ecipients with 8 unrelated marrow transplant recipi-
nts. All patients in both groups were adult patients
ith acute leukemia in complete remission who re-
eived the same conditioning regimen, GVHD pro-
hylaxis, and supportive treatment. The median times
o ANC 0.5  109/L (33 days of UCBT versus 20.5
ays of bone marrow transplantation [BMT]; P  .05)
nd platelets to 50  109/L (48 days of UCBT
ersus 25.5 days of BMT; P  .05) were signiﬁcantly
onger in the UCBT group.
The correlation between CD34 cell dose and
ngraftment has also been evaluated. In the Duke
niversity series, patients who received 1.37 
05/kg CD34 cells had more rapid platelet recovery.
o correlation between CD34 cell dose and engraft-
ent was discerned in the multicenter study by
aughlin et al. [21], although in that study, EFS was
mproved in patients who received 1.2  105
D34 cells per kilogram.
The optimal nucleated cell dose and CD34 cell
ose in UCB grafts remain to be determined. In the
ontext of pediatric patients, the recommended nucle-
ted cell doses include 1.0 107/kg, 1.5 107/kg, and
.0  107/kg [28,38,39]. A CD34 cell dose of 1.7 
05/kg has been established as the threshold dose for
atients at the University of Minnesota [20]. On the
asis of the clinical data available so far for adult
nrelated UCBT [21,23], it is not unreasonable to
uggest that UCB should contain a cryopreserved cell
ose of at least 1.8  107 nucleated cells per kilogram
nd 1.2  105 CD34 cells per kilogram.
raft-versus-Host Disease
Published data from most of the CB registries
10,11,17,18,20,32] have shown that despite the infu-
ion of HLA class I and II disparate grafts, the inci-
ence and severity of acute and chronic GVHD
mong unrelated UCB recipients have thus far been
ower than previously reported in recipients of
atched UD marrow or partially matched family
ember marrow allografts [40-44]. In these series of
CBT recipients, most of whom are children, the
verall incidence of grade II to IV acute GVHD and a
B&MTrade III to IV acute GVHDwere in the range of 30%
o 50% and 10% to 20%, respectively.
Barker et al. [36], in a matched-pair analysis, dem-
nstrated a similar rate of acute and chronic GVHD
etween pediatric recipients of 0 to 3 HLA antigen–
ismatched UD UCB grafts and those who received
LA-matched UD marrow grafts. Another compara-
ive study by Rocha et al. [31] has demonstrated a
ower incidence of acute GVHD (hazard ratio, 0.50)
nd chronic GVHD (hazard ratio, 0.24) in a cohort of
ediatric patients who received mismatched unrelated
CB grafts compared with unrelated, unmanipulated
one marrow recipients. The association between
LA disparity and the risk of GVHD in unrelated
CB recipients remains unclear; most studies demon-
trate no correlation [10,16,17,20,28]. However, in an
pdated multivariate analysis of data from the largest
eries published so far, Rubinstein and Steven [45]
ave shown a signiﬁcant association between acute
VHD and HLA disparity. The incidence of grade
II to IV acute GVHD in patients with no mismatch,
-antigen HLA mismatch, and 2-antigen mismatch
ere 8%, 19%, and 28%, respectively (P  .006).
To date, no matched-pair comparative study has
een performed in the adult patient population to
ompare the incidence of GVHD between unrelated
CBT and UD marrow transplantation. The re-
orted series in adults have shown 40% to 60% and
0% to 22% incidences of grade II to IV and grade III
o IV acute GVHD, respectively, and a 26% to 90%
ncidence of chronic GVHD (Table 1). Given the
ncreased patient age in these adult patients (age is
ecognized as a risk factor for GVHD [46,47]), the
ncidence of acute and chronic GVHD among these
dult patients is considered acceptable as compared
ith the pediatric unrelated UCBT series, which have
eported 33% to 44% and 11% to 22% incidences of
rade II to IV and grade III to IV GVHD, respec-
ively, and a 0% to 25% incidence of chronic GVHD
10,11,20,31]. Also, with many of these patients re-
eiving HLA-mismatched UCB grafts, the incidence
f grade III to IV acute GVHD in these unrelated
CB recipients compares favorably to the 35% to
5% incidence reported in recipients of HLA-
atched bone marrow from adult UDs who received
tandard prophylaxis against GVHD [41-44,48]. It is
oteworthy that the reported incidence of chronic
VHD showed a wide range from 26% to 90%. In
omparison, chronic GVHD develops in 55% to 75%
f patients who receive HLA-matched BMT from
Ds [41-44,48]. The variability in the reported rate of
VHD may be attributed to the following factors: (1)
ifferences in conditioning regimens and GVHD pro-
hylaxis regimens used by different centers, (2) differ-
nces in supportive care, (3) transplant center effect
49], (4) the disease and disease status of the patients,
nd (5) subjective elements and inconsistency involved
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8n the grading of GVHD by different teams. The
ssociation between HLA mismatch and GVHD has
ot been addressed in these adult series except in the
eport by Laughlin et al. [21], which did not observe
ny inﬂuence of histocompatibility on the severity of
cute GVHD.
oxicity and Transplant-Related Mortality
Several series with predominantly pediatric pa-
ients receiving unrelated UCB grafts have reported
00-day and 1-year TRM in the range of 27% to 39%
nd 30% to 44%, respectively [16,20,31,36]. Infection
nd acute GVHD were the main causes of death
ithin the ﬁrst day after transplantation. Rocha et al.
31] reported in their pediatric studies that the inci-
ence of 100-day TRM in the unrelated marrow re-
ipients was signiﬁcantly higher as compared with the
nrelated UCB recipients. However, no such differ-
nce was detected in another series reported by the
roup from the University of Minnesota [36]. The
niversity of Minnesota series, which consisted pre-
ominantly of children, has shown the important as-
ociation between TRM and CD34 dose, recipient’s
ge, and development of grade III to IV acute GVHD.
owever, no correlation could be discerned between
LA and TRM [20].
A relatively higher incidence of TRM at 100 days
as been observed in the adult series, ranging between
3% to 56%. The high nonrelapse mortality in these
eries is partially attributable to the high-risk nature of
he patient population. Several prognostic factors have
een found to predict higher TRM. The Eurocord
ata, which showed a higher 180-day TRM in adult
nrelated UCB (56%) as compared with the pediatric
atients (32%), found a lower 100-day TRM among
atients with disease in chronic phase or remission,
umber of nucleated cells infused 2.0  107/kg, and
ransplantation performed after January 1998 [9,39].
n the Laughlin et al. [21] series, the TRM for the ﬁrst
00 days was 50%, and nearly half of the deaths were
ue to infection. Notably, improved EFS was seen
mong patients who received UCB grafts with CD34
ells 1.2  105/kg [21]. A study from a Spanish
enter on 27 adult recipients of unrelated UCB has
hown a 100% incidence of infectious episodes, a 55%
ncidence of bacteremia, a 58% incidence of CMV
ntigenemia, and an 11% incidence of fungal infec-
ions. In that study, the reported TRM at day 100 was
7%, and 80% of the deaths were related to infec-
ions. It is important to note that the study observed
ore than half of the infections occurring after my-
loid recovery [50].
The increased risk of infection within the ﬁrst 100
ays after transplantation may be related to delayed
ngraftment, GVHD, or impaired immune recovery
11,21]. With the data from the University of Minne- tota showing the profound inﬂuence of CD34 cell
ose on the rate of engraftment, TRM, and survival
nd also the observation that most recipients of UCB
ith an adequate cell dose do not die of infection [20],
t is believed that prolonged neutropenia is the main
ontributory cause of increased risk of infection.
owever, the Spanish experience [50], which showed
high incidence of infection after myeloid recovery,
ertainly suggests the inﬂuence of impaired immune
ecovery and GVHD in causing infections.
Organ toxicity associated with the intensive treat-
ent administered to patients before UCBT is an-
ther leading cause of nonrelapse mortality in adult
CB recipients. In the Laughlin et al. [21] series, 35%
f the deaths were related to the preparative regimen.
ecause of toxicities from the intensive conditioning
egimens to nonmarrow organs, such as gut, liver,
ung, and heart, UCBT with myeloablative prepara-
ive regimens has been restricted to patients younger
han 50-55 years of age; none of the series reported
hus far has included patients older than 60 years of
ge. Such restrictions based on age are problematic in
hat many hematologic malignancies typically present
fter the age of 50 years [51], thus making many
atients ineligible for UCBT despite having suitably
atched unrelated UCB grafts with adequate cell
oses. These limitations have given an impetus for
xploring the use of NM regimens for UCBT, as will
e discussed later in this article.
Finally, given the heterogeneity of the patient
opulation and the conditioning and GVHD prophy-
axis regimens used, as well as the supportive care
endered at the different centers, it is difﬁcult to have
reliable evaluation of the possible effect of different
retransplantation variables on TRM. However,
mong all the different prognostic variables that have
een evaluated, the cell dose of the UCB graft seems
o be the only one that can be manipulated [20].
uture efforts in decreasing TRM should therefore
ocus not only on improving transplant methodology
nd supportive care, but also on improving the UCB
ell dose.
isease Relapse
As with UD BMT, relapse is another common
ause of death after UCBT. Concerns raised about the
ossibility of an increased risk of leukemia recurrence
n UCBT recipients are derived from the following
onsiderations: (1) there is a close association of graft-
ersus-leukemia (GVL) with GVHD in allograft re-
ipients, such that patients who develop either acute
r chronic GVHD experience a much lower risk of
elapse [52,53]; (2) the incidence and severity of both
cute and chronic GVHD seemed to be less after
ransplantation of CB progenitors than after marrow
ransplantation [10,11,17,18,20,31]; and (3) immatu-
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Cord Blood Transplants in Adults
Bity and diminished cytotoxicity of infused CB lym-
hocytes [54,55] could further impair the immune-
ediated anti malignancy effect. However, 3 previous
eports comparing UCBT and unmanipulated BMT
romHLA-identical siblings [8] and from UDs [31,36]
mong children with leukemia have shown a similar
isk of relapse. The 2-year incidence of relapse in
hildren receiving unrelated UCBT ranges between
7% and 40%, and disease status at transplantation is
he predominant risk factor [16,20,31].
In comparison with the pediatric series, the data
n the adult patient population are scanty and incon-
lusive because of a smaller number of patients,
horter duration of follow-up, and difference in pa-
ient selection. The reported incidence of relapse as
he cause of death has ranged widely between 6%
21,24] and 35% [26]. The variability in the relapse
ate is likely due to heterogeneity in patient selection.
urvival and Outcome
Two comparative studies in pediatric patients have
hown no difference in survival between patients re-
eiving UD UCBT and UD BMT [31,36]. Most of
he studies, which mainly involved children with UD
CBT, have reported 1- and 2-year overall survival in
he range of 29% to 58% and 35% to 53%, respec-
ively [10,20,28,31,36]. The prognostic factors that
ave been found to inﬂuence survival include (1) dis-
ase status at transplantation [9,16], (2) HLA match
11,20], (3) infused nucleated cell dose per kilogram of
ecipient’s weight [10,11,28], (4) CD34 cell dose per
ilogram of recipient’s weight [20,28], (5) age of re-
ipient [11,28], (6) grade III to IV GVHD [20], and (7)
MV status of recipient [10].
In contrast to the series in children, it is difﬁcult to
ave a reliable evaluation of the possible effect of
arious pretransplantation variables on the survival of
he adult UCB recipients because of the heterogeneity
f the patient population and the limitations of small
atient numbers and a short duration of follow-up.
he available series thus far have reported a survival
utcome with a wide range, from 19% to 76% for
-year overall survival and from 21% to 53% for
-year EFS. In the Laughlin et al. [21] series, the
resence of a higher CD 34 cell dose in the UCB
raft was associated with improved EFS. In both the
uke University series and the Spanish series [22], age
t transplantation had a signiﬁcant effect on survival.
he Eurocord data have shown that a good risk status
t transplantation and an infused nucleated dose of
1  107/kg are favorable factors for survival [23].
he superior survival of a small group of Japanese
atients with high-risk myelodysplastic syndrome has
rovided further evidence that an adequate cell dose
as a critical effect on survival [30]. Of note, none of
hese studies has demonstrated any association be- a
B&MTween HLA disparity and survival. However, in a re-
ent review with 861 unrelated UCBT recipients from
he placental blood program of the New York Blood
enter, which included 181 (21%) patients aged 18
ears and 170 patients (20%) weighing 60 kg, Ru-
instein and Steven [45] demonstrated in a multivar-
ate analysis that HLA match was an independent
redictor of EFS in the subset of patients with acute
ymphoblastic leukemia (ALL), acute myeloid leuke-
ia, or CML.
A study from the St. Louis Cord Blood bank,
eported in abstract form, compared the outcome of
3 adults (with median age of 39 years [range, 17-66
ears] and a median weight 66 kg [range, 41-131 kg])
ith that of 83 children (with a median age of 7 years
range, 1-16 years] and a median weight of 25 kg
range, 6-78 kg]) [56]. The adult patients received a
igniﬁcantly lower cell dose, with a median total nu-
leated cell dose of 2.7  107/kg (range, 1.1-5.3 
07/kg) and a median CD34 cell dose of 1.4  105/kg
range, 0.2-4.4  105/kg), as compared with the chil-
ren, who had a median total nucleated cell dose of
.8  107/kg (range, 1.3-24.8  107/kg) and a median
D34 cell dose of 3.3  105/kg (range, 0.5-20.8 
05/kg). The times to neutrophil and platelet recovery
ere similar between the 2 groups. The estimated
-year survival was comparable between the adults and
he children (64% for adults; 60% for children).
aken together, these results suggest that UCB
hould be considered as an alternative stem cell source
or adults, especially when an unrelated marrow donor
s not available in a timely fashion.
ummary
UCB contained a sufﬁcient number of HSCs to
chieve engraftment in adult patients with a lower-
han-anticipated risk of severe acute GVHD, even
hen HLA-disparate grafts were infused. The use of
CB as a source of stem cells allows allografting to be
ffered to more patients, many of whom do not have
matched sibling or UD, to allow allogeneic therapy
s the only chance to cure the underlying disease. The
esults thus far suggest that UD UCBT can result in
ong-term DFS in many of these patients. Similar to
he pediatric series, clinical experience in the adult
atients has also documented the importance of graft
ell dose in determining engraftment and survival.
he critical threshold dose below which engraftment
nd survival become signiﬁcantly inferior remains to
e deﬁned in a larger study with a longer follow-up.
n the basis of current results, it seems that the UCB
raft, which contains at least 1.8  107 nucleated cells
er kilogram and 1.2 105 CD34 cells per kilogram,
s acceptable for adult recipients. It is hoped that the
dvantage of a lower GVHD incidence without any
pparent increase in relapse in UCBT will offset any
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1dverse effect of reduced cell dose on survival. As in
he pediatric setting, TRM remains the main obstacle
or successful UCBT in adults. With the profound
nﬂuence of UCB cell dose (both nucleated cell dose
nd CD34 cell dose) on engraftment, survival and,
robably, TRM in the adult setting, future research
hould also focus on increasing the cell dose of the
CB graft.
M STEM CELL TRANSPLANTATION
NM stem cell transplantation (NST) or transplan-
ation with reduced-intensity conditioning was pro-
osed initially on the basis of the rationale that the
herapeutic beneﬁt of an allogeneic transplantation is
artially related to the crucial immune-mediated
raft-versus-malignancy effect. The concept of graft-
ersus-malignancy as the pivotal therapeutic compo-
ent of allogeneic transplantation is supported by the
bservations from clinical studies that (1) patients with
cute and chronic GVHD have a reduced risk of
elapse [52,53]; (2) patients with syngeneic BMT and
fter T cell–depleted allotransplantation have a higher
ncidence of relapse compared with other allogeneic
onors [53,57]; and (3) patients with a relapsed ma-
ignancy after allogeneic transplantation can be rein-
uced into complete remission without any chemo-
herapy by donor lymphocyte infusion [58-60].
NST, with its reduced-intensity preparative regi-
ens, makes allogeneic transplantation applicable to
atients with relative contraindications to myeloabla-
ive regimens. This dose-reduced conditioning nour-
shed the hope that patients would experience less
ransplant-related mortality with fewer infections and
ess GVHD. This approach was based on the hypoth-
sis that the attenuated conditioning regimens would
1) decrease the mucosal and tissue damage, (2) min-
mize the release of inﬂammatory cytokines, (3) de-
rease the incidence of infections, (4) reduce the inci-
ence of GVHD, and (5) ultimately allow powerful
lloimmune responses to eradicate disease processes
hile minimizing the initial treatment-related mor-
idity and mortality. The development of the strategy
ith the NST preparative regimen not only revolu-
ionizes but also overturns some of the long-held
ogmas in clinical stem cell transplantation. First, it is
o longer correct to assume that myeloablative che-
oradiotherapy is required to “create space” for do-
or cell engraftment or to ensure leukemia cure. This
pproach relies more on the creation of “immunologic
pace” for engraftment rather than the more tradi-
ional approach of creating “physical space” by the
ntensive chemoradiotherapy. Second, responses in
enal cell cancer challenge the assumption that solid
umors are unsuitable targets for graft-versus-tumor
ffects because tumor bulk and chemoresistance ren- k
0er them beyond the reach of stem cell allograft ap-
roaches [61].
The clinical outcomes of patients undergoing al-
ogeneic transplantation with this novel reduced-in-
ensity preparative regimen have been published by
everal groups [13,14,62-65]. Most of these patients
epresent a poor prognostic group, with either re-
apsed chemoresistant or primary refractory hemato-
ogic diseases. The most frequently reported diseases
reated with this modality include chronic hemato-
ogic malignancies such as chronic lymphocytic leuke-
ia, low-grade non-Hodgkin lymphoma, and multi-
le myeloma, followed less frequently by refractory
nd more aggressive diseases, including acute leuke-
ias, lymphoma, and solid tumors. The early results
re encouraging, with lower treatment-related mor-
ality and mortality. However, the median follow-up
or most of these studies is short; hence, the evidence
or a sustained antitumor effect is very limited, and the
ong-term survival beneﬁt remains to be established.
lthough these reduced-intensity preparative regi-
ens have decreased immediate procedural mortality,
hey have not resulted in a low incidence of GVHD, as
xpected in preclinical studies. GVHD remains the
redominant cause of death after such transplanta-
ions [12,13,61]. It is apparent that NST and subse-
uent donor lymphocyte infusion are changing the
ime frames in which acute and chronic GVHD man-
fest; hence, the standard GVHD deﬁnitions may be
ess applicable. Furthermore, because the preparative
egimen does not contribute signiﬁcantly to the anti-
alignancy effect, the risk of disease progression after
ransplantation remains higher compared with the
yeloablative approach. It has been shown that NST
s more applicable for more indolent malignancies, for
hich there is less urgency for immediate treatment,
r for diseases that are susceptible to graft-versus-
alignancy effects. The clinical outcome is disap-
ointing in active, aggressive malignancies, in which
he rapidity of tumor growth outpaces the develop-
ent of the graft-versus-malignancy effect [62].
M Transplantation with UCB Progenitor Cells
Given the excellent tolerance of these nonmyelo-
blative (NM) regimens and the high rate of alloen-
raftment, there has been considerable interest in
hese transplantation strategies by using UCB as a
ource of hematopoietic stem cell support after NM
reparative regimens. NST with UCB provides an
pportunity for immunotherapy for older patients,
icker patients, and patients without suitable donors,
ho are not eligible for this potentially curative ap-
roach. However, there is increased concern about
raft rejection with this approach. In NST with adult
elated donor or UD stem cells, the infusion of cyto-
ine-mobilized peripheral blood progenitor cells with
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Cord Blood Transplants in Adults
Bhigher cell dose may overcome the major HLA
arrier [66,67], with resultant stable donor cell recov-
ry over the autologous recovery. This may not be
easible in the setting of UCBT with NM condition-
ng therapy because there are on average 2 log fewer
ells infused than would be considered standard for
atched sibling or UD transplantation. The clinical
utcome of 2 patients with malignant lymphoma by
sing this novel approach was ﬁrst reported by inves-
igators at Duke University [68]. In their study, 2
atients with relapsed lymphoma who had no matched
iblings, partially matched family members, or
atched UDs successfully underwent NM condition-
ng therapy followed by infusion of 4 of 6 matched
D UCB cells at the nucleated cell dose of 2.9 and
.5  107/kg. The conditioning regimens consisted of
udarabine 30 mg/m2 and cyclophosphamide 500
g/m2 daily for 4 days with antithymocyte globulin
0 mg/kg/d for 3 days. Cyclosporin A (CyA) and
rednisolone were given for acute GVHD prophy-
axis. Both patients had 100% donor engraftment by
he third month after transplantation and remained in
emission 6 and 12 months after transplantation. The
avorable outcome demonstrates the feasibility of the
ismatched unrelated UCB cells, even with the NM
reparative regimens.
he Duke University Experience
Between November 2000 and September 2002, 10
atients underwent NST with UCB at Duke Univer-
ity Medical Center. The median age of these patients
as 51 years (range, 19-62 years), their median weight
as 65.7 kg (range, 49.1-99 kg), and the median num-
er of nucleated cells per kilogram infused was 2.07 
07/kg (range, 1.07-5.53  107/kg). The diagnoses
ncluded relapsed mantle cell lymphoma (n  2), my-
lodysplastic syndrome (n  2), metastatic melanoma
n  1), relapsed high-grade lymphoma (n  1), high-
isk ALL (n  2), relapsed acute myeloid leukemia
n  1), and CML (n  1). Eight patients received
rafts disparate at 2 HLA loci, and the other 2 had 1
LA locus–disparate graft.
All patients received ﬂudarabine 30 mg/m2 and
yclophosphamide 500 mg/m2 daily for 4 days (days
5 to 2) with antithymocyte globulin 30 mg/kg/d
or 3 days (days 3 to 1). Acute GVHD prophylaxis
onsisted of CyA and methylprednisolone for all pa-
ients except 2, who were given CyA and mycopheno-
ate mofetil (MMF). All patients received subcutane-
us 5 g/kg of G-CSF or granulocyte-macrophage
olony-stimulating factor until neutrophil engraft-
ent.
Six (60%) of the 10 patients demonstrated donor
himerism between 4 weeks and 6 months. Three
atients became fully donor, whereas 3 patients had
ransient low levels of detectable donor cells, but these 1
B&MTells did not persist. The remaining 4 (40%) patients
ever demonstrated any evidence of donor engraft-
ent. The median time to neutrophil recovery with
NC 500/L for all 10 patients was 8 days (range,
-32 days), and the median time to platelet recovery
ith a platelet count exceeding 20000/L was 3 days
range, 0-61 days). Three patients never had a nadir
NC 500/L, whereas 5 patients never had a nadir
latelet count 20000/L. Five of the 7 patients who
id not engraft experienced transient grade 4 cytope-
ia before autologous hematopoietic reconstitution.
Of the 3 patients who achieved full donor chimer-
sm, 1 developed grade 3 steroid-refractory acute
VHD of the gut at 4 months after transplantation;
he other patient developed chronic GVHD 9 months
fter transplantation. One patient subsequently died
f disseminated aspergillosis and 1 of complications
rom and debilitation after cerebral infarction. With a
edian follow-up of 7 months (range, 2-24 months), 5
50%) patients have died: 3 from disease progression
r relapse without evidence of engraftment, 1 from
ungal infections in the sixth month, and 1 to a cere-
ral infarction 13 months after transplantation while
n complete remission and with full donor chimerism.
ive (50%) patients were alive at the last follow-up.
nly 2 of the surviving patients were in complete
emission: one patient sustained full donor chimerism
t 2 years after transplantation, and the other patient
ad a low donor signal at 8 months after transplanta-
ion. The estimated overall survival and EFS at 2 years
or this high-risk group were 36% (95% conﬁdence
nterval, 16%-55%) and 27% (95% conﬁdence inter-
al, 12%-42%), respectively. It is important to note
hat no treatment-related mortality was observed
ithin the ﬁrst 100 days after transplantation.
M UCBT—Results from Other Transplant
enters
A similar approach has also been reported by in-
estigators at the University of Colorado Health Sci-
nces Center (Table 2). McSweeney et al. [69] re-
orted on 4 patients with advanced hematologic
alignancies (age, 25-78 years) who received 5 of 6 or
of 6 HLA-matched UCB after being conditioned
ith ﬂudarabine 30 mg/m2  3 and TBI 200 cGy.
yA and MMF were used as postgrafting immuno-
uppression. The ranges of nucleated cell doses and
D34 cells were 0.75 to 1.3  107/kg and 1.0 to
.0  104/kg, respectively. Two of the 3 evaluable
atients had stable engraftment. Mild biopsy-proven
kin GVHD developed in 1 patient but resolved spon-
aneously.
Cairo et al. [70] demonstrated the feasibility of
educed-intensity allogeneic transplantation by using
- to 2-antigen–mismatched UCB with a median nu-
leated cell dose of 5  107/kg (range, 0.22-9.5 
7 0 /kg) and a median CD34 cell dose of 1.95 
11
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105/kg (range, 0.11-3.7  107/kg) on 6 children and
dolescent patients with both malignant and nonma-
ignant diseases. All patients were 21 years old and
ere conditioned with a ﬂudarabine-based regimen.
ngraftment occurred in all patients except 1, and a
urvival of 50% was attained.
Transplantation with reduced-intensity condi-
ioning was also evaluated by investigators from the
niversity of Minnesota in a cohort of high-risk pa-
ients with hematologic malignancies [71]. In their
tudy, unrelated UCB grafts with a median nucleated
ell dose of 3.7  107/kg (range, 1.6-6.0  107 /kg)
ere infused into 43 patients (median age of 49.5 years
range, 22-65 years]) after they received 2 types of
M conditioning regimens: ﬂudarabine 200 mg/m2,
BI 200 cGy, and busulphan 8 mg/kg (Flu/Bu/TBI)
or the initial 21 subjects and ﬂudarabine 200 mg/m2,
able 2. Summary of Results of Nonmyeloablative Unrelated Umbilica
Variable
Present Study
(Duke University) M
eference No.
o. of patients 10
ge, y, median (range) 51 (19-62) 64.5
iagnosis NHL, MDS, AML, MEL, ALL HD,
reparative regimen F  C  ATG F 
VHD prophylaxis CyA  PDN (n  8) CyA
CyA  MMF (n  2)
ell dose, median
(range)
NC (107/kg) 2.07 (1.07-5.53) 1.1 (
CD34 (106/kg) 0.13 (0.05-0.96) NA
CD3 (106/kg) 4.6 (2.02-22.82) NA
ngraftment (n) 3
edian days to ANC
>500/L (range) 8 (0-32)
edian days to platelet
>20 000/L (range) 3 (0-61)
rade II to IV aGVHD/
cGVHD (n) 1/1
utcome Alive: n  5 Alive
Disease free: n  3 PR:
OS: 36% at 2 y
GVHD indicates acute graft-versus-host disease; cGVHD, chroni
count; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic
lymphoblastic leukemia; HD, Hodgkin disease; CLL, chronic
drome; NBL, neuroblastoma; HM, hematologic malignancies; F
total body irradiation; Bu, busulphan; CyA, cyclosporin A; MM
not available; CI, cumulative incidence; PR, partial remission; O
The results include a patient who received a peripheral blood stem
The results refer to patients given F  Bu  TBI 200 cGy as a c
The results refer to patients given F  C  TBI 200 cGy as a coBI 200 cGy, and cyclophosphamide 50 mg/kg (Flu/ p
2y/TBI) for the subsequent 22 subjects. All patients
eceived GVHD prophylaxis with CyA and MMF.
he median time to neutrophil recovery of 0.5 
09/L was 26 days (range, 12-30 days) for the Flu/Bu/
BI recipients but was only 9.5 days (range, 5-28
ays) for the Flu/Cy/TBI recipients. The cumulative
ncidence of engraftment for Flu/Bu/TBI and Flu/Cy/
BI recipients was 76% and 94%, respectively. De-
pite the use 1 to 2 HLA-antigen mismatched grafts in
3% of the recipients, the cumulative incidence of
rade II to IV GVHD and grade III to IV GVHD for
he entire cohort of patients was 44% and 9%, respec-
ively. The DFS of these high-risk subjects was also
avorable: 24% at 1 year for Flu/Bu/TBI recipients
nd 41% at 1 year for Flu/Cy/TBI recipients.
In the experience reported by Ballen et al. [72], 6
atients with solid tumors and 1 patient with lym-
lood Transplantation
ey et al. Cairo et al. Barker et al.
70 71
6 43
17 (0.5-21)* 49.5 (22-65)
LL, NHL HD, THAL, WAS, NBL HM
0 cGy) F  Bu  ATG (n  5)
F  Bu  TBI (200
cGy) (n  21)
F  C (n  1)
F  C  TBI (200
cGy) (n  22)
F FK506  MMF CyA  MMF
) 5.07 (0.22-9.5)* 2.6 (1.6-3.8)†
3.2 (1.1-5.1)‡
04) 0.19 (0.011-0.37)* .37 (.11-.81)†
.43 (.11-.103)‡
) NA 6 (2-15)†
5 (2-12)‡
4* CI  76%†
CI  94%‡
15 (1-29)* 26 (12-30)†
9.5 (5-28)‡
8.5 (1-31)* NA
A 2/1* CI for aGVHD  44%
CI for cGVHD  21%
Alive: n  5 OS: 39% at 1 y
Disease free: n  4 DFS: 31% at 1 y
versus-host disease; NC, nucleated cell; ANC, absolute neutrophil
me; AML, acute myeloid leukemia; MEL, melanoma; ALL, acute
cytic leukemia; THAL, thalassemia; WAS, Wiskott-Aldrich syn-
rabine; ATG, antithymocyte globulin; C, cyclophosphamide; TBI,
ophenolate mofetil; PDN, prednisolone; FK506, tracrolimus; NA,
rall survival; DFS, disease-free survival
ransplant.
ning regimen.
ing regimen.l Cord B
cSween
69
5
(25-78)
AML, C
TBI (20
 MM
1.75-1.3
(0.01-0.
(1.4-3.3
2
NA
NA
1/N
: n  3
n  1
c graft-
syndro
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, ﬂuda
F, myc
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Beceived unrelated UCBT after conditioning with 100
Gy of TBI. No GVHD prophylaxis was given to any
f these patients. The median number of CD34 and
D3 cells per kilogram was 3.1  104/kg (range,
.1-10.7 104/kg) and 1.7 106/kg (range, 0.5-3.7
06/kg), respectively. However, none of these patients
chieved a tumor response or evidence of donor chi-
erism.
MMUNE RECONSTITUTION
mmune Reconstitution in Myeloablative UCBT
atients
Immune reconstitution after allogeneic BMT has
een studied extensively [73-76]. However, only a few
eports, all of which enrolled a limited number of
atients, addressed the immune reconstitution of
CBT recipients after myeloablative regimens [77-
2]. The lower number of lymphocytes infused in the
CB and their immaturity presents a potential prob-
em for immune recovery and T-cell reconstitution
fter UCBT. This issue is of paramount importance
ith respect to the occurrence of relapse, GVHD, and
nfectious complications. Moretta et al. [78] showed
hat immune recovery after either related or unrelated
CBT was similar to that after matched related or
nrelated BMT. Niehues et al. [81] demonstrated that
he median time to both CD3 and CD4 cell recon-
titution was 11.7 months, whereas the median time of
D8 cell reconstitution was 7.9 months. The char-
cteristic inversion of the CD4/CD8 ratio, as ob-
erved after BMT [73], was not seen after UCBT
80-82]. Recovery of natural killer (NK) cells and B
ells occurred quickly, taking a median of 3 and 6
onths, respectively.
A similar study on immune reconstitution, but also
ncluding functional immune recovery, was under-
aken by investigators at the Indiana School of Med-
cine [80]. The T-cell response to mitogen stimulation
ecovered between 6 and 9 months; B-cell function, as
ssessed by immunoglobulin production, remained in
he normal range after transplantation, with nadirs
etween 1 and 3 months; and NK cell lytic function
ecovered at 1 month. There was no relationship be-
ween the time to recovery of T-, B-, or NK-cell
umbers and nucleated cells per kilogram or CD34
ells per kilogram. Neither was there a correlation
etween either numerical or functional immune re-
overy and the incidence or grade of infectious com-
lications. However, there was a weak association
etween the recovery of the response to phytohemag-
lutinin and pokeweed mitogen and nucleated cells
er kilogram infused.
Investigators at Duke University Medical Center
nalyzed the immunologic reconstitution after my-
loablative unrelated UCBT in adults and children to r
B&MTetermine the source of the regenerated T-cell pool
79]. UCB is phenotypically naive but T-cell replete,
llowing for T-cell reconstitution through either cen-
ral or peripheral mechanisms. Reconstitution of im-
unity after UCB occurred over 2 to 3 years for both
dult and pediatric recipients. Both patient groups
ventually demonstrated a normal lymphocyte count
ith a quantitatively normal distribution of B cells, T
ells, and NK cells. The sources of T cells, however,
eem strikingly different. Pediatric patients demon-
trated signiﬁcant numbers of signal-joint T-cell re-
eptor excision circle (TREC)–containing T cells
tarting within 1 year after transplantation, indicating
hat the T cells were recent thymic emigrants. In
ontrast, adult recipients did not demonstrate any
ignal-joint TREC–containing T cells until 1.5 to 2
ears after transplantation, and then only at relatively
ow levels. These results suggest that adult recipients
f CB had a very slow recovery of T-cell numbers and
unctions. By using a complementarity-determining
egion 3 repertoire to measure the changes in T-cell
eceptor diversity occurring with restoration of thy-
ic function, skewing of T-cell repertoires was dem-
nstrated in adults and children at 12 to 18 months
fter transplantation. However, this recovered to
ear-normal diversity at 2 to 3 years after transplan-
ation. The T-cell repertoire seemed more diverse
arlier in children (at 1 to 2 years after transplanta-
ion) than in adults (at 3 to 4 years after transplanta-
ion). The analysis provides evidence that early T-cell
ecovery after UCBT occurs primarily through the
eripheral expansion of adoptively transferred donor
cells and results in skewing of the T-cell repertoire.
hese data also underscore the importance of preserv-
ng the integrity of thymic function, thus allowing the
apid recovery of T cells with a complex diversity. NM
onditioning regimens in this respect, with their de-
reased toxicity, may afford the advantages of enhanc-
ng the ability of the recipient thymus to support
ifferentiation of de novo–derived T cells of donor
rigin compared with the more toxic regimens, which
ay produce more substantial thymic injury.
ifferences in UCB Immune Reconstitution
etween Myeloablative and NM Regimens
Comparison of immune reconstitution between
yeloablative and NST recipients has been per-
ormed by several groups on adult hematopoietic stem
ells (peripheral blood progenitor cells and bone mar-
ow). When comparing allogeneic peripheral blood
tem cell recipients after an NST regimen versus after
myeloablative regimen, Morecki et al. [83] observed
decrease in the absolute number of CD4 cells,
hich was accompanied by an increase in CD8 cells;
his led to an inverted CD4/CD8 cell ratio. The NM
onditioning regimen was found to result in early
econstitution of immune responses in vitro, and this
13
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1eneﬁt may translate into faster development of effec-
ive immune responses against residual host-type ma-
ignant and abnormal nonmalignant hematopoietic
ells. On the basis of complementarity-determining
egion 3 size spectratype analysis, Friedman et al. [84]
emonstrated that patients who received NST condi-
ioning together with either bone marrow or periph-
ral blood stem cells exhibited more rapid reconstitu-
ion of T-cell repertoire complexity [85].
Limited data are currently available on immune
econstitution of UCB recipients after NST prepara-
ive regimens. Immune recovery in 5 recipients of
CBT after an NST regimen was compared with
ecovery in adults recipients of UCB after a myelo-
blative regimen by investigators at Duke University
85]. The absolute lymphocyte count reached normal
evels in adults 6 to 12 months after NST transplan-
ation with UCB, in contrast to 24 months in adults
ho received a myeloablative regimen [79]. At 12
onths after transplantation, the numbers of pheno-
ypically naive (CD45RA) T cells were higher in
hose who received the NST regimen. The rapidly
xpanding naive population outnumbered the mem-
ry cells in the recipients of NST regimen. The T-cell
epertoire in UCB recipients treated with an NST
egimen was markedly more diverse and robust com-
ared with the repertoire in those who received the
yeloablative regimen at similar time points. TRECs,
hich are generated within the thymus and identify
ew thymic emigrants and those that have not divided,
ere detected 12 months after transplantation in the
ST recipients. This compared favorably to the de-
ayed detection of TRECs at 18 to 24 months among
ecipients of myeloablative regimens. Thus, in adults
ho received an NST preparatory regimen, the quan-
itative and qualitative recovery of T cells occurs
hrough rapid peripheral expansion. The ability of
atients receiving NST transplantation to recover
ithin a few months suggests that the peripheral
iches in which T cells can proliferate are preserved in
hese patients compared with those who receive my-
loablative regimens. Moreover, the presence of
REC-positive cells within 1 year suggests that thy-
ic recovery is likewise accelerated in recipients of
ST compared with myeloablative regimens. The
avorable results of T-cell recovery after NST suggest
hat it may be possible to have an excellent outcome
ith an unrelated mismatched UCBT in adult pa-
ients. Patients have a rapid recovery of T cells with a
omplex diversity. The primary difference between
ecipients of ablative and nonablative regimens was
he extent of physiologic damage caused by the pre-
aratory regimen. When the damage is relatively
ild, as in the NM regimen, the donor T cells are able
o expand effectively in the periphery, and the devel-
pment of new T cells through the thymus is also
ccelerated compared with the rate of development in c
4hose who receive ablative regimens. Alternatively, the
ower incidence of GVHD in NST may also play an
mportant role in preservation of the peripheral and
entral niches for T-cell development.
X VIVO EXPANSION AND TRANSPLANTATION OF
ULTIPLE UNITS OF UCB
One of the major limitations of using UCB as the
ource of stem cells for transplantation is the low cell
ose, which not only adversely affects both the rate of
ematopoietic recovery and the probability of survival
10,11,86], but also results in a higher risk of graft
ailure as compared with BMT. In addition, data from
he University of Minnesota have demonstrated the
rofound importance of the CD34 cell dose on the
ate of engraftment, treatment-related mortality, and
urvival in patients receiving UD UCBT [71]. The
isk of engraftment failure is substantially higher and
anges from 10% to 25% in series with adult patients
18 years old, 40 kg, or both) [21,24,25]. In addi-
ion, the lack of available donor immune effector cells
or adoptive cellular immunotherapy is the other ma-
or limitation associated with using unrelated UCB.
To circumvent these limitations after UCBT,
tudies have been performed to investigate the possi-
ility of expanding the UCB progenitors ex vivo to
mprove engraftment. This area of investigation is
articularly interesting because in vitro studies have
hown that expansion can be increased in UCB com-
ared with bone marrow cells. The use of cytokine
ocktails, including stem cell factor, G-CSF, and
egakaryocyte growth and differentiation factor, is
ffective in preclinical studies [87]. In a report from
he University of Colorado, the infusion of UCB that
as expanded ex vivo in conjunction with the unex-
anded fraction in adults (weighing 54-116 kg) and
ediatric patients with high-risk malignancies after
yeloablative therapy resulted in a low incidence of
ngraftment failure and equivalent times to engraft-
ent of neutrophils and platelets as reported for
maller pediatric patients [88]. Of note, the protocols
sed in this study consisted of both an expanded frac-
ion and an unexpanded fraction. The unexpanded
raction was included because of the concern that ex
ivo expansion may exhaust long-term engrafting
ells. The same group of investigators has also ad-
ressed this issue of the short- and long-term engraft-
ng potential of ex vivo expanded CB by performing
n experiment with a fetal sheep xenogeneic trans-
lantation model. In that study, the ex vivo expanded
ells was be able to provide rapid short-term engraft-
ent, but the long-term potential of expanded cells
ay be compromised. It is for this reason that trans-
lantation of the unexpanded CB products was in-
luded in the studies to ensure durable long-term
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Cord Blood Transplants in Adults
Bonor engraftment [89]. The overall beneﬁt of this
trategy has not been fully determined and deserves
urther investigation.
Another avenue of research is the possibility of
sing several CB units to increase the stem cell yield.
n a sheep xenograft model of human hematopoiesis, a
ombination of human UCB units enhanced the
hort-term, but not long term, repopulating capacity
f human UCB cells [90]. Barker et al. [91] ﬁrst
eported successful transplantation of 2 partially
LA-matched units of UCB into a 53-year-old, 83-kg
oman with an accelerated phase of chronic myelog-
nous leukemia and no bone marrow donor. A double
himera with both units contributing to hematopoiesis
as attained on the basis of a restriction fragment
ength polymorphism analysis performed 60 days after
ransplantation. The same group of investigators re-
ently updated the clinical outcome of 23 high-risk
dult patients (median age, 47 years; range, 18-60
ears]) with hematologic malignancies [92]. Using
oth myeloablative and NM conditioning regimens,
hey demonstrated a high incidence of engraftment
94%) without an increase in severe GVHD (the cu-
ulative incidences of grade II-IV and grade III-IV
cute GVHD were 47% and 10%, respectively). The
ata support the principle that transplantation of 2
mmunologically distinct UCB units is not associated
ith crossed immunologic rejection. These observa-
ions provide the most compelling argument for fo-
using future investigations on evaluating the efﬁcacy
f ex vivo expansion of 2 units of UCB in larger
linical trials and also for exploring the potential ad-
antages of the transplantation of multiple units of
CB after NM preparative regimens [92].
EMAINING QUESTIONS AND FUTURE DIRECTIONS
OR UCBT IN ADULTS
UCB from UDs has been increasingly used as an
lternative source of hematopoietic stem cells in adults
ith hematologic diseases that can be cured only with
llogeneic stem cell transplantation. The ability to
chieve stable mixed or full donor chimerism by using
educed-intensity preparative regimens, with success-
ul eradication of primary disease in the absence of
evere treatment-related toxicity in preliminary clini-
al studies, signiﬁes another advancement in the ﬁeld
f transplantation and immunobiolology. However,
here are several unresolved issues and remaining
uestions regarding the utility of this novel strategy.
hat Is the Optimal UCB Cell Dose Required for
dult Patients?
Most of the series on unrelated UCBT have em-
hasized the paramount importance of nucleated cell
ose in engraftment and survival, and HLA disparity N
B&MTas a less convincing effect [10,11,16,45]. Two of the
tudies have indicated that a higher CD34 cell dose
artially overcomes the negative effect of HLA for
ach level of HLA disparity [20,93]. Transplantation
f a UCB graft containing 1.5  107 nucleated cells
er kilogram or1.7 107 CD34 cells per kilogram
f recipient weight has been suggested to be the min-
mum cell dose required for pediatric patients [20,28].
he optimal cell dose for unrelated UCBT in adults is
et to be determined. As noted previously, 2 previous
tudies have demonstrated the threshold for more
avorable engraftment among adult recipients to be a
ucleated cell dose of 1.7  107/kg and 1.87 
07/kg [9,21,23]. However, very little is known about
he minimal cell dose for durable engraftment in the
ontext of UCBT after an NST conditioning regi-
en. With NST conditioning and mismatched UDs,
he concern over rejection of UCB is increased. The
nderlying diseases for which the transplantation was
erformed also affect the risk of engraftment failure,
ith a trend toward greater risk of graft failure in
ecipients with a history of a bone marrow failure
yndrome, CML, hemoglobinopathy, or storage dis-
ase [10,11,94,95].
With a median nucleated cell dose of 2.07 
07/kg recipient body weight infused, durable engraft-
ent occurred in 3 of the 10 patients from the Duke
niversity series. As for the University of Minnesota
eries, a median nucleated dose of 3.7  107/kg recip-
ent body weight resulted in a 76% to 94% probability
f engraftment [71]. Potential strategies to overcome
he risk of graft rejection include the use of a graft
ith a higher cell dose, a graft that has been expanded
x vivo, combinations of multiple CB units, and the
se of modiﬁed protocol that conveys a higher degree
f pretransplantation immunosuppression to over-
ome transfusion-induced sensitization in patients
ith bone marrow failure syndromes and hemoglobi-
opathies. Optimizing postgrafting immunosuppres-
ion, such as including the use of MMF and modifying
he duration of GVHD prophylaxis, might be another
romising approach in the context of allogeneic
ransplantation after an NST preparative regimen
14,96,97].
hat Is the Difference in Overall Efficacy
etween Myeloablative and NST UCBT?
In contrast to UCBT with a myeloablative condi-
ioning regimen, the published series on NST with
CB have involved either primarily a small cohort of
atients with refractory hematologic malignancies or
atients who were otherwise poor candidates for a
onventional transplantation approach. The follow-up
eriod is usually too short and the data are too scanty
o determine the overall beneﬁt of NST with UCB as
he source of stem cells. Furthermore, because most
STs are performed in situations in which standard
15
t
a
N
t
p
b
o
i
h
i
a
s
m
e
r
t
t
i
s
s
f
a
a
v
b
d
d
m
p
s
p
t
f
t
c
p
c
i
I
v
d
[
m
t
a
T
i
t
c
H
o
P
3
[
u
a
4
r
B
4
a
t
g
d
U
i
U
p
t
r
n
v
c
e
r
i
C
[
c
U
r
I
v
t
t
r
[
w
b
b
p
h
t
a
m
a
a
p
p
m
m
i
a
p
m
L.-P. Koh and N. J. Chao
1ransplantations would not be considered, no compar-
tive studies between myeloablative regimens and
ST would be, or would be likely to be, performed in
he near future.
The indications for NST versus a myeloablative
reparative regimen need to be carefully deﬁned. The
eneﬁt of reduced toxicity with NST regimens may be
ffset by the loss of cytoreduction of the tumor cells
nduced by high-dose chemotherapy. The use of NST
as generally been more successful in patients with
ndolent lymphoid malignancies or malignancies that
re susceptible to GVL effects, such as CML. It is less
uccessful in patients with aggressive malignancies or
alignancies that seem relatively insensitive to GVL
ffects, such as ALL and high-grade lymphoma. The
apid proliferation of these malignancies may outpace
he developing immune response. Given the limita-
ion of the cell dose of UCB and the logistic problem
n donor recall, NST with UCB does not afford the
ame advantage as in NST with adult hematopoietic
tem cells, in which the transplant provides a platform
or repeated delivery of adoptive cellular immunother-
py with donor lymphocyte infusion. In the case of an
ggressive malignancy in which the delayed graft-
ersus-malignancy effect cannot be relied on, it may
e more beneﬁcial to use a preparative regimen (re-
uced-toxicity ablative regimen) that provides some
isease control [12,98] and also facilitates engraft-
ent.
One important issue that deserves attention is the
otential of NST with UCB to minimize the inpatient
tay and improve the quality of life in the peritrans-
lantation period while reducing cost. All patients in
he Duke University series had transplantation per-
ormed largely in the outpatient setting. The median
ime for hematopoietic recovery is shorter than with
onventional UCBT. Longer follow-up with more
atients will be needed to determine the incidence of
hronic GVHD and the quality of life of such recip-
ents.
s the Incidence of GVHD Similar in Ablative
ersus NST Regimens?
UCBT has been associated with a reduced risk of
eveloping severe GVHD in children and adults
8,21], even when cells from partially HLA-mis-
atched donors are used. NST was introduced with
he hope that patients would experience less GVHD
fter reduced-intensity conditioning regimens [61,99].
his was based on the hypotheses that (1) less tissue
njury would occur because of the lower dose of cyto-
oxic agents and (2) the induction of mixed chimerism
ould reduce the incidence of GVHD [100,101].
owever, GVHD remains the most signiﬁcant cause
f morbidity and mortality after NST conditioning.
reviously published reports on NST have shown a
8% to 60% incidence of grade II to IV acute GVHD
613,14,62,63,65,102]. It remains to be seen whether
nrelated UCB used in the NST regimen can result in
n incidence of grade II to IV lower than the range of
0% to 60%, as reported in previous adult series
eceiving myeloablative unrelated UCBT [21,22,25,27].
arker et al. [71] have demonstrated in their cohort of
3 adult patients that the incidence of grade III to IV
cute GVHDwas low (9%). This is encouraging given
he fact that 1 to 2 HLA antigen-mismatched UCB
rafts were used in 93% of their patients.
In addition, studies on immune recovery have pro-
uced optimism that patients undergoing NST with
CB may experience less GVHD. These studies on
mmune reconstitution among patients receiving
CBT or BMT [79,84,85,103] have demonstrated the
otential beneﬁt of minimizing thymic damage
hrough an NST conditioning regimen. The early
estoration of thymic function will allow early domi-
ance of the thymus-dependent phase and thus pre-
ent the exclusive expansion of peripheral T-cell
lones. In addition, the increased level of T-cell rep-
rtoire complexity observed in patients receiving NST
egimens may lead to increased numbers of alloreactive
mmunoregulatory cells, such as those marked by CD4
D25 expression, and thereby suppress GVHD
104,105]. Nevertheless, determining whether the in-
idence and severity of GVHD related to NST with
CB are lower than with myeloablative UCBT will
equire clinical trials in comparable groups of patients.
s the Incidence of Infection Similar in Ablative
ersus NST Regimens?
Adult UCBT recipients are at risk for opportunis-
ic infections for at least 2 to 3 years after transplan-
ation. Infection may account for half of all treatment-
elated deaths after UCBT after an ablative regimen
11]. Apart from the prolonged neutropenia associated
ith myeloablative UCBT, the risk of infection may
e an intrinsic property of UCB, because UCB has
een shown to be phenotypically naive [106], to ex-
and slowly in response to antigen stimulation, to
ave a higher threshold for cytokine stimulation, and
o possess a lower effective cytotoxicity relative to
dult donor T-cell controls [106,107]. Moreover, thy-
ic production of new T cells is substantially delayed
nd remains limited in adult recipients of UCB after
n ablative preparative regimen.
Patients who receive UCBT after a nonablative
reparative regimen have a shorter period of neutro-
enia and more rapid immune reconstitution with a
ore diverse T-cell repertoire [85]. Whether the
ore favorable immune recovery can be translated
nto faster development of effective immune responses
gainst opportunistic infections and, therefore, im-
roved transplantation outcome remains to be deter-
ined in clinical trials.
Data from previous studies suggest that recipients
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Cord Blood Transplants in Adults
Bf NM HSCT may have different, but not necessarily
ecreased, risks for invasive bacterial, viral, and fungal
nfections [108]. One of the main reasons is due to the
se of differing NM or reduced-intensity regimens,
nd each of these regimens varies in its hematologic
nd nonhematologic toxicities. The risk of infection in
oth myeloablative and allogeneic NST recipients is
ependent on the degree of immunoablation/myelo-
blation, the severity of GVHD and its immuno-
uppressive therapies, and the rate of immune
econstitution. Preliminary results suggest that NM
onditioning regimens may decrease the risk of bac-
erial infections associated with mucosal damage and
ersistent neutropenia; however, risks for late viral
nd fungal infections persist during severe GVHD
108]. It is currently unclear whether the incidence of
VHD is similar between ablative and NM UCBT
ecipients. Because previous reports have not shown a
ower incidence of GVHD in NM HSCT recipients,
t is not surprising to see infectious complications
merging as a major contributory cause of nonrelapse
ortality in NM UCBT recipients.
As opposed to the data that have been gathered
egarding CMV infections after BMT, the knowledge
egarding the risk of CMV infection after myeloabla-
ive and NM UCBT is sparse. Rubinstein et al. [11]
howed that CMV infection after unrelated UCBT
ccurred in 23% of seropositive recipients and 3% of
eronegative patients. CMV seropositivity has been
dentiﬁed to be associated with a higher risk of
VHD, higher treatment-related mortality, and
oorer survival outcome in the studies by the Euro-
ord Transplant Group and the group from the Uni-
ersity of Minnesota [10,20]. Saavedra et al. [50] re-
orted a 41% incidence of CMV reactivation within
he ﬁrst 100 days after transplantation in 27 adult
atients receiving unrelated UCB grafts after a my-
loablative preparative regimen. CMV disease oc-
urred in only 1 patient, and there was no CMV-
elated mortality. In a Japanese single-institutional
tudy of 28 adult UCBT recipients, the use of UCB
nits from UDs containing serologically and geneti-
ally multiple mismatches in the HLA loci was asso-
iated with a high probability of CMV reactivation
109].
In patients receiving BMT, it is thought that the
oss of immunocompetent host cells after the myelo-
blative regimen and the delayed recovery of donor
raft–derived immunity contributes to the risk of
MV infections. The risk is further potentiated by the
resence of acute GVHD [110], whereby the recovery
f the CMV-speciﬁc T-cell response is further im-
aired. In NM HSCT, it was hypothesized that the
ncomplete eradication of host T cells and the pro-
onged presence of host immunity after NST might
rovide some protection against early infection as
ompared with conventional myeloablative transplan- p
B&MTation. However, clinical studies have shown that this
mmunologic advantage did not confer any superior
utcome in terms of CMV infections. Investigators
rom Seattle have shown that the risk of CMV-asso-
iated disease does not seem to be lower with NM
egimens. It is important to note that the time of onset
f CMV disease was signiﬁcantly delayed in the NM
ompared with the myeloablative HSCT recipients;
ost cases occurred after day 100 [111]. These data
re in contrast to 2 other studies. Chakrabarti et al.
112] found a 90% incidence of CMV infections
ithin 35 days after transplantation by using an
lemtuzumab (Campath-1H) and ﬂudarabine–based
M preparative regimen. In another study involving
1 NM transplant recipients given a preparative reg-
men that contained ﬂudarabine and antithymocyte
lobulin, Mohty et al. [113] found a high incidence
65%) of CMV infection before day 50. These appar-
ntly conﬂicting ﬁndings may be explained by the
ifference in the intensity of immunosuppression of
he preparative regimens and the GVHD prophylaxis
chedule. The inclusion of ﬂudarabine, a highly im-
unosuppressive agent, in most NM regimens may
esult in a higher incidence of CMV infection [114]. A
igher risk of CMV infection may also be attributed to
he use of a CyA and MMF combination as GVHD
rophylaxis in many NST recipients, because this reg-
men has been found to have synergistic and more
rofound immunosuppressive effects on T cells as
ompared with the CyA and MTX combinations
112,115]. It is important that investigators be aware
f these pitfalls, which may secondarily increase trans-
lant toxicity. Further studies are needed to deﬁne
ppropriate preventive, surveillance, and therapeutic
trategies. With several NM conditioning regimens
ith differing immunosuppressive potentials being ex-
lored at different centers, the timing of infections
ay differ, and it is therefore imperative to determine
he risk for early and late viral infections for each
egimen. For patients receiving NM unrelated
CBT, the effect of favorable immunologic recovery
n the risks of CMV infections remains to be deter-
ined in multiple larger studies, especially consider-
ng the substantial variation between conditioning
egimens.
hat Is the Optimal NST Conditioning Regimen
nd GVHD Prophylaxis?
The optimal intensity of preparative regimens is
ncertain, and several factors must be considered, in-
luding the aggressiveness of the underlying disease,
he age of the patient, the immunocompetence of the
ecipients, and the genetic disparity between the do-
or and recipient. A wide range of NST conditioning
egimens has been used. These regimens are designed
ot to eradicate the underlying malignancy but to
rovide sufﬁcient immunosuppression to facilitate en-
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1raftment. The question posed is how immunosup-
ressed the patients need to be to overcome the risk of
raft rejection. The beneﬁt of reduced toxicity with
ST regimens may be offset by the loss of cytoreduc-
ion induced by high-dose chemotherapy. As noted
reviously, the use of NST has generally been less
uccessful in aggressive malignancies, which are likely
o recur rapidly and outpace immune reconstitution.
iven the increasing indication of applying NST in
lder patients with refractory malignancies, future ef-
orts may focus on the development of a more toler-
ble regimen that has broad-spectrum antineoplastic
nd immunosuppressive activity that not only facili-
ates engraftment, but also provides some disease con-
rol. The challenge becomes greater when mis-
atched UCBT is used, where HLA disparity and a
ower cell dose is associated with a higher risk of graft
ejection. Further studies are necessary to deﬁne the
est regimen that reduces the risk of rejection without
ncreasing the risk of relapse and regimen-related tox-
city.
GVHD remains the leading cause of death among
atients receiving NST, and optimizing the GVHD
rophylaxis regimen is of paramount importance in
mproving the transplantation outcome. Although
cute GVHD tends to be less severe after an NST
reparative regimen, it frequently occurs after the
arly termination of immunosuppressive therapy
116]. Inclusion of Campath-1H has recently been
eported to produce a low rate of GVHD [117]. The
se of Campath-1H or any other maneuver that ef-
ectively results in T-cell depletion of the graft may
ave adverse effects, including slow immune reconsti-
ution resulting in an increased risk of viral infection
112] and stable mixed chimerism that could abrogate
he GVL effect of the allograft and lead to relapse of
he underlying malignancy. Longer-term follow-up
ill be required to assess whether these potential dis-
dvantages will overweigh the lower GVHD-related
orbidity and mortality.
ONCLUSION
UCB is a viable alternative to bone marrow and
eripheral blood as a source of stem cells capable of
ematopoietic reconstitution for adults when an un-
elated marrow donor is not available. UCBT after an
ST preparative regimen is an exciting new approach
hat provides an option for patients who are otherwise
xcluded from conventional HSCT, including elderly
r medically inﬁrm patients with no matched sibling
onor. Preliminary results have shown that such an
pproach can be associated with timely engraftment
ith full donor chimerism. Comparison between my-
loablative and NST approaches will be needed before
his therapy can be considered for younger patients
8ligible for myeloablative transplantation. At the mo-
ent, the use of NST UCBT cannot be encouraged
utside of clinical trials or selected patients. The fu-
ure challenge will be to develop strategies to optimize
he chance of early and durable engraftment, as well as
o minimize the risk of GVHD and transplant-related
eath.
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